| Product Code: ETC6529846 | Publication Date: Sep 2024 | Updated Date: Dec 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, Brunei saw significant import shipments of large molecule drug substances from top exporting countries including Malaysia, Singapore, Ireland, USA, and Australia. Despite a declining compound annual growth rate (CAGR) of -12.32% from 2020 to 2024 and a sharp growth rate decrease of -57.43% from 2023 to 2024, the market remained highly concentrated with a very high Herfindahl-Hirschman Index (HHI). This indicates a continued dominance of key players in the market, showcasing a stable yet competitive landscape for large molecule drug substance CDMO imports in Brunei.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Brunei Large Molecule Drug Substance CDMO Market Overview |
3.1 Brunei Country Macro Economic Indicators |
3.2 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Brunei Large Molecule Drug Substance CDMO Market - Industry Life Cycle |
3.4 Brunei Large Molecule Drug Substance CDMO Market - Porter's Five Forces |
3.5 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Service, 2021 & 2031F |
3.6 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.7 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 Brunei Large Molecule Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for large molecule drug development in Brunei due to rising prevalence of complex diseases. |
4.2.2 Favorable government regulations and incentives supporting the growth of the large molecule drug substance CDMO market in Brunei. |
4.2.3 Growing investments in research and development activities by pharmaceutical companies in the region. |
4.3 Market Restraints |
4.3.1 Limited availability of skilled workforce specialized in large molecule drug development in Brunei. |
4.3.2 High initial setup costs and infrastructure requirements for establishing large molecule drug substance CDMO facilities in the country. |
5 Brunei Large Molecule Drug Substance CDMO Market Trends |
6 Brunei Large Molecule Drug Substance CDMO Market, By Types |
6.1 Brunei Large Molecule Drug Substance CDMO Market, By Service |
6.1.1 Overview and Analysis |
6.1.2 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume, By Service, 2021- 2031F |
6.1.3 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Manufacturing, 2021- 2031F |
6.1.4 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021- 2031F |
6.1.5 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021- 2031F |
6.1.6 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Development, 2021- 2031F |
6.1.7 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume, By Cell Line Development, 2021- 2031F |
6.1.8 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021- 2031F |
6.2 Brunei Large Molecule Drug Substance CDMO Market, By Source |
6.2.1 Overview and Analysis |
6.2.2 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume, By Mammalian, 2021- 2031F |
6.2.3 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume, By Microbial, 2021- 2031F |
6.2.4 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Brunei Large Molecule Drug Substance CDMO Market, By End-user |
6.3.1 Overview and Analysis |
6.3.2 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume, By Biotech Companies, 2021- 2031F |
6.3.3 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume, By CRO, 2021- 2031F |
6.3.4 Brunei Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
7 Brunei Large Molecule Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Brunei Large Molecule Drug Substance CDMO Market Export to Major Countries |
7.2 Brunei Large Molecule Drug Substance CDMO Market Imports from Major Countries |
8 Brunei Large Molecule Drug Substance CDMO Market Key Performance Indicators |
8.1 Percentage increase in the number of collaborations between local pharmaceutical companies and international CDMOs. |
8.2 Average time taken from project initiation to commercial production for large molecule drug substances. |
8.3 Rate of adoption of advanced technologies and manufacturing processes in the large molecule drug substance CDMO sector in Brunei. |
9 Brunei Large Molecule Drug Substance CDMO Market - Opportunity Assessment |
9.1 Brunei Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Service, 2021 & 2031F |
9.2 Brunei Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Source, 2021 & 2031F |
9.3 Brunei Large Molecule Drug Substance CDMO Market Opportunity Assessment, By End-user, 2021 & 2031F |
10 Brunei Large Molecule Drug Substance CDMO Market - Competitive Landscape |
10.1 Brunei Large Molecule Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 Brunei Large Molecule Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |